Special article: Strategies for the global eradication of poliomyelitis by the year 2000

New England Journal of Medicine

Volumn 325, Issue 25, 1991, Pages 1774-1779

  Wright, Peter F ^a   Kim Farley, Robert J ^b   de Quadros, Ciro A ^c   Robertson, Susan E ^b   Scott, Robert Mcn ^b   Ward, Nicholas A ^b   Henderson, Ralph H ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Pan American Health Organizations   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; MEASLES VACCINE; POLIOMYELITIS VACCINE; TETANUS TOXOID; TRIPLE VACCINE;

DISEASE CONTROL; GENETIC STABILITY; HEALTH CARE COST; HUMAN; IMMUNIZATION; MEDICAL RESEARCH; POLIOMYELITIS; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SEROTYPE; VACCINE PRODUCTION; WORLD HEALTH ORGANIZATION;

AMERICAS; DEVELOPING COUNTRIES; FORECASTING; HEALTH SERVICES NEEDS AND DEMAND; HUMAN; IMMUNIZATION; PAN AMERICAN HEALTH ORGANIZATION; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; RESEARCH; WORLD HEALTH ORGANIZATION;

EID: 0026409822     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199112193252504     Document Type: Article

References (30)

1. Global eradication of poliomyelitis by the year 2000. In: Forty-first World Health Assembly, Geneva, 2–13 May 1988: resolutions and decisions annexes. Geneva: World Health Organization, 1988:26. (Resolution WHA41.28.)
2. Expanded programme on immunization. In: Forty-second World Health Assembly, Geneva, 8–19 May 1989: resolutions and decisions annexes. Geneva: World Health Organization, 1989:33. (Resolution WHA42.32.)
3. Henderson RH. The World Health Organization's plan of action for global eradication of poliomyelitis by the year 2000. Ann N Y Acad Sci 1989; 569: 69–85
4. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13: 926–39
5. Pan American Health Organization. Director announces campaign to eradicate poliomyelitis from the Americas by 1990. Bull Pan Am Health Organ 1985; 19: 213–5
6. Update: progress toward eradicating poliomyelitis from the Americas. MMWR 1990; 39: 557–61
7. De Quadros CA, Andrus JK, Olive J-M, et al. Eradication of poliomyelitis: progress in the Americas. Pediatr Infect Dis 1991; 10: 222–9
8. Pan American Health Organization. Poliovirus surveillance. Wkly Bull 1991; 6: 38
9. Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985; 151: 420–36
10. Manual for the virological investigation of poliomyelitis. Geneva: World Health Organization, 1990. (WHO/EPI/CDS/Polio/90.1.)
11. Global Advisory Group. Expanded programme on immunization. Part I. Wkly Epidemiol Rec 1990; 65: 5–11
12. Lemon SM, Robertson SE. Global eradication of poliomyelitis: recent progress, future prospects, and new research priorities. Prog Med Virol 1991; 38: 42–55
13. Sutter RW, Patriarca PA, Brogan S, et al. Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children. Lancet 1991; 338: 715–20
14. Rico-Hesse R, Pallansch MA, Nottay BK, Kew OM. Geographic distribution of wild poliovirus type 1 genotypes. Virology 1987; 160: 311–22
15. Jansen RW, Siegl G, Lemon SM. Molecular epidemiology of human hepatitis A virus defined by an antigen-capture polymerase chain reaction method. Proc Natl Acad Sci U S A 1990; 87: 2867–71
16. Hogle JM, Chow M, Filman DJ. Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 1985; 229: 1358–65
17. Dorval BL, Chow M, Klibanov AM. Stabilization of poliovirus against heat inactivation. Biochem Biophys Res Commun 1989; 159: 1177–83
18. Nkowane BM, Wassilak SGF, Orenstein WA, et al. Vaccine-associated paralytic poliomyelitis: United States: 1973 through 1984. JAMA 1987; 257: 1335–40
19. Minor PD, John A, Ferguson M, Icenogle JP. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccine. J Gen Virol 1986; 67: 693–706
20. Dunn G, Begg NT, Cammack N, Minor PD. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J Med Virol 1990; 32: 92–5
21. Toyoda H, Kohara M, Kataoka Y, et al. Complete nucleotide sequences of all three poliovirus serotype genomes: implication for genetic relationship, gene function and antigenic determinants. J Mol Biol 1984; 174: 561–85
22. Racaniello VR, Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 1981; 214: 916–9
23. Almond JW. The attenuation of poliovirus neurovirulence. Annu Rev Microbiol 1987; 41: 153–80
24. Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 1989; 56: 855–65
25. Ren RB, Costantini F, Gorgacz EJ, Lee JJ, Racaniello VR. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell 1990; 63: 353–62
26. Chumakov KM, Powers LB, Noonan KE, Roninson IB, Levenbook IS. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci U S A 1991; 88: 199–203
27. Burke KL, Dunn G, Ferguson M, Minor PD, Almond JW. Antigen chimaeras of poliovirus as potential new vaccines. Nature 1988; 332: 81–2
28. Kohara M, Abe S, Komatsu T, Tago K, Arita M, Nomoto A. A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain. J Virol 1988; 62: 2828–35
29. Potential use of new poliovirus vaccines: memorandum from a WHO meeting. Bull World Health Organ 1990; 68: 545–8
30. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva: World Health Organization, 1988